About us

RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas.

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.

RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.

The Russian pharmaceutical company NovaMedica is a key company in RusNanoMedInvest’s portfolio. With NovaMedica, RMI promotes the transfer of know-how and intellectual property rights to its portfolio companies’ developments to Russia, in order to implement and promote them in the Russian market. NovaMedica’s strategy targets the research, registration and Russian localization of intellectual property rights for innovative products and technologies, the development and implementation of its own R&D projects, as well as the creation of a modern R&D center and high-tech pharmaceutical GMP production. 

RMI Partners is a member of Invest Europe, the association which is representing Europe’s private equity, venture capital and infrastructure sectors. 


News

  • 19 September 2017

    Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share. This includes the exercise in full by the underwriter of its option to purchase up to 1,400,000 additional shares of common stock. The offering was led by Bain Capital Life Sciences with participation from new and existing investors, raising gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.